Investment firm Tikvah Management LLC plans to oppose SomaLogic Inc.’s (Nasdaq: SLGC) planned $1 billion merger with California-based Standard BioTools Inc. (Nasdaq: LAB), making Tikvah the second major investor to stake out a position against the deal in the last week or so.